Company intelligence / Profile preview

Hemovent

Aachen, North Rhine-Westphalia, Germanyhemovent.com ↗

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Hemovent’s MOBYBOX™ system has received CE marking and has been introduced into select clinical settings throughout Europe. Published in vivo studies have shown “excellent long-term safety and physiologic efficacy.” The company was pursuing FDA clearance for the US market and registration in China as of late 2021.

Therapeutic areas: PulmonologyCardiovascular
Modalities: DeviceMedical device (Extracorporeal Membrane Oxygenation / Extracorporeal Life Support system)
Industry: Therapeutic Medical Devices

Partnerships

Integration with MicroPort group post-acquisition; no major external pharma partnerships disclosed.

Beyond the preview

Go deeper on Hemovent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemovent.

Explore the full profile